Effectiveness and safety of Atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour;Wirksamkeit und sicherheit von Atosiban vs. pulsatiler applikation von fenoterol bei der behandlung vorzeitiger wehen

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 213, Issue 5, 2009, Pages 201-206

  Nonnenmacher, A ^a   Hopp, H ^a   Dudenhausen, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adverse eff ects; Effi cacy; Preterm labour; Tocolysis

Indexed keywords

ATOSIBAN; BETAMETHASONE; FENOTEROL; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEAR; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NERVOUSNESS; OUTCOME ASSESSMENT; PREMATURE LABOR; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TREMOR;

ADOLESCENT; ADULT; FEMALE; FENOTEROL; HORMONE ANTAGONISTS; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; TOCOLYTIC AGENTS; TREATMENT OUTCOME; VASOTOCIN; YOUNG ADULT;

EID: 70449337948     PISSN: 09482393     EISSN: 14391651     Source Type: Journal    
DOI: 10.1055/s-0029-1225640     Document Type: Article

References (30)

1. Gomez R, et al. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am 1997 11 135-176
2. Rath W, Dudenhausen JW. Alte und neue Tokolytika eine aktuelle Diskussion um Nutzen, Nebenwirkungen und Kosten. Geburtshilfe Frauenheilkd 2003 63 119-123
3. Rath W, Bartz C. Medikamentöse Wehenhemmung aktueller Stand. Geburtshilfe Frauenheilkd 2005 65 570-579
4. Rettwitz-Volk. Epidemiologische Aspekte der Frühgeburtlichkeit. Perinatal Medizin 1996 8 15-18
5. ACOG. ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol 2001 98 709-716
6. ACOG. ACOG practice bulletin. Management of preterm labor. Number 43, May 2003. Int J Gynaecol Obstet 2003 82 127-135
7. Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2001 period linked birth/infant death data set. Natl Vital Stat Rep 2003 52 1-28
8. Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep 2004 53 1-29
9. Beinder E. Vorzeitige Wehen: Diagnostik und leitlinenbasierte Therapie. CME Praktische Fortbildung 2006 1 26-34
10. Gyetvai K, et al. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999 94 869-877
11. Romero R, et al. The role of systemic and intrauterine infection in preterm parturition. Ann N Y Acad Sci 1991 622 355-375
12. Hillier SL, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995 333 1737-1742
13. Keirse MJ. The history of tocolysis. BJOG 2003 110 (Suppl); %20 94-97
14. Spatling L, et al. Bolus tocolysis: treatment of preterm labor with pulsatile administration of a beta-adrenergic agonist. Am J Obstet Gynecol 1989 160 713-717
15. Anotayanonth S, et al. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004 CD004352
16. Caritis SN, et al. Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol 1989 161 32-35
17. King JF, et al. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988 95 211-222
18. Lamont RF. The pathophysiology of pulmonary oedema with the use of beta-agonists. BJOG 2000 107 439-444
19. Moutquin JM, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000 182 1191-1199
20. The European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet Gynecol Scand 2001 80 413-422
21. French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001 98 177-185
22. The Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001 108 133-142
23. Husslein P, et al. Atosiban versus usual care for the management of preterm labor. J Perinat Med 2007 35 305-313
24. Herzog S, et al. Pulsatile vs. continuous parenteral tocolysis: comparison of side effects. Eur J Obstet Gynecol Reprod Biol 1999 85 199-204
25. Goodwin TM, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994 170 474-478
26. Papatsonis D, et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005 20 CD004452
27. Romero R, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000 182 1173-1183
28. Shim JY, et al. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG 2006 113 1228-1234
29. Valenzuela GJ, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000 182 1184-1190
30. Meirowitz NB, et al. Value of maintenance therapy with oral tocolytics: a systematic review. J Matern Fetal Med 1999 8 177-183